KMKevin Joseph Maloy

Kevin Joseph Maloy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin Joseph Maloy has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Update: Induction of Inflammatory Bowel Disease in Immunodeficient Mice by Injection of Naïve CD4+ T cells (T Cell Transfer Model of Colitis)

    by Claire F. Pearson, Kevin J. Maloy

    The intestinal inflammation induced by injection of naïve CD4+ T cells into lymphocyte‐deficient hosts (more commonly known as the T cell transfer model of colitis) shares many features of idiopathic inflammatory bowel disease (IBD) in humans, such as epithelial cell hyperplasia, crypt abscess formation, and dense lamina propria lymphocyte infiltration. As such, it provides a useful tool for studying mucosal immune regulation as it relates to the pathogenesis and treatment of IBD in humans. In the IBD model described here, colitis is induced in Rag (recombination‐activating gene)‐deficient mice by reconstitution of these mice with naïve CD4+CD45RBhi T cells through adoptive T cell transfer. Although different recipient hosts of cell transfer can be used, Rag‐deficient mice are the best characterized and support studies that are both flexible and reproduceable. As described in the Basic Protocol, in most studies the transferred cells consist of naïve CD4+ T cells (CD45RBhi T cells) derived by fluorescence‐activated cell sorting from total CD4+ T cells previously purified using immunomagnetic negative selection beads. In a Support Protocol, methods to characterize colonic disease progression are described, including the monitoring of weight loss and diarrhea and the histological assessment of colon pathology. © 2024 The Author(s). Current Protocols published by Wiley Periodicals LLC.Basic Protocol: Induction of IBD in Rag‐deficient mice by the transfer of naïve CD4+CD45RBhi T cellsSupport Protocol: Monitoring development of colitis


  • Open Access

    MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T-cell responses

    by Cornelia E. Heuberger, Alina Janney, Nicholas Ilott, Alice Bertocchi, Sebastian Pott, Yisu Gu, Mathilde Pohin, Matthias Friedrich, Elizabeth H. Mann, Claire Pearson, et al.


  • Open Access

    MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T cell responses

    by C. E. Heuberger, A. Janney, N. Ilott, A. Bertocchi, S. Pott, Y. Gu, M. Pohin, M. Friedrich, E. H. Mann, C. Pearson, et al.

    Although intestinal epithelial cells (IECs) can express major histocompatibility complex class II (MHC II), especially during intestinal inflammation, it remains unclear if antigen presentation by IECs favours pro- or anti-inflammatory CD4 + T cell responses. Using selective gene ablation of MHC II in IECs and IEC organoid cultures, we assessed the impact of MHC II expression by IECs on CD4 + T cell responses and disease outcomes in response to enteric bacterial pathogens. We found that intestinal bacterial infections elicit inflammatory cues that greatly increase expression of MHC II processing and presentation molecules in colonic IECs. Whilst IEC MHC II expression had little impact on disease severity following Citrobacter rodentium or Helicobacter hepaticus infection, using a colonic IEC organoid-CD4 + T cell co-culture system, we demonstrate that IECs can activate antigen-specific CD4 + T cells in an MHC II-dependent manner, modulating both regulatory and effector Th cell subsets. Furthermore, we assessed adoptively transferred H. hepaticus -specific CD4 + T cells during intestinal inflammation in vivo and report that IEC MHC II expression dampens pro-inflammatory effector Th cells. Our findings indicate that IECs can function as non-conventional antigen presenting cells and that IEC MHC II expression fine-tunes local effector CD4 + T cell responses during intestinal inflammation.

  • Faculty Opinions recommendation of A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.

    by Kevin Maloy

    This comprehensive study used a nanoparticle- and liposome-formulated vaccine containing mRNA that has been modified to be non-immunogenic, to induce tolerance to auto-antigens and thus inhibit autoimmune disease in mice. The data convincingly demonstrated that systemic administration of non-immunogenic mRNA encoding an epitope from myelin oligodendrocyte glycoprotein (MOG) could inhibit experimental autoimmune encephalomyelitis (EAE), a widely used mouse model of multiple sclerosis (MS). Importantly, the non-immunogenic mRNA vaccine also ameliorated EAE when given therapeutically in two different disease models. Mechanistic investigations revealed that the non-immunogenic mRNA vaccine induced the development and expansion of MOG-specific regulatory T cells (Treg) while limiting the development of pathogenic Th1 and Th17 effector T cells. Finally, they showed that the induced MOG-specific Treg were able to engender 'bystander' tolerance to additional CNS auto-antigens. Although further assessment in humans is required, these findings support the possibility that personalised non-immunogenic mRNA vaccines may be developed as a therapeutic treatment for organ-specific autoimmune diseases.

  • Open Access

    Novel gut pathobionts confound results in a widely used mouse model of human inflammatory disease

    by Samuel C. Forster, Simon Clare, Benjamin S. Beresford-Jones, Katherine Harcourt, George Notley, Mark Stares, Nitin Kumar, Amelia T. Soderholm, Anne Adoum, Hannah Wong, et al.

    The mammalian gut microbiota consists of hundreds of anaerobic bacterial species that shape intestinal homeostasis and influence host immune responses. Although the causal roles of specific human gut bacterial species in health and disease are emerging, the role of indigenous gut bacteria in driving immunophenotypic variability in mouse models of human disease remains poorly understood. We performed a large-scale experiment using 579 laboratory mice designed to identify and validate the causes of disease variability in the widely used dextran sulphate sodium (DSS) mouse model of inflammatory bowel disease. Using microbiome analysis, coupled with machine learning and targeted anaerobic culturing, we identified and isolated the novel gut pathobiont species Duncaniella muricolitica and Alistipes okayasuensis and fulfilled Koch’s postulates in mice to show that each pathobiont exerts dominant effects in the DSS model leading to variable treatment responses. We show these pathobiont species are common, but not ubiquitous, in mouse facilities around the world, raising experimental design opportunities for improved mouse models of human intestinal diseases.


  • Open Access

    Disrupted Iron Metabolism and Mortality during Co-infection with Malaria and an Intestinal Gram-Negative Extracellular Pathogen

    by Luara Isabela dos Santos, Thais Abdala Torres, Suelen Queiroz Diniz, Ricardo Gonçalves, Gustavo Caballero-Flores, Gabriel Núñez, Ricardo Tostes Gazzinelli, Kevin Joseph Maloy, Lis Ribeiro Do V. Antonelli


  • Open Access

    Why do intestinal epithelial cells express MHC class II?

    by Cornelia Heuberger, Johanna Pott, Kevin Joseph Maloy

    Summary: Intestinal epithelial cells (IECs) constitute the border between the vast antigen load present in the intestinal lumen and the mucosal immune compartment. Their ability to express antigen processing and presentation machinery evokes the question whether IECs function as non‐conventional antigen‐presenting cells. Major histocompatibility complex (MHC) class II expression by non‐haematopoietic cells, such as IECs, is tightly regulated by the class II transactivator (CIITA) and is classically induced by IFN‐γ. As MHC class II expression by IECs is upregulated under inflammatory conditions, it has been proposed to activate effector CD4+ T (Teff) cells. However, other studies have reported contradictory results and instead suggested a suppressive role of antigen presentation by IECs, through regulatory T (Treg)‐cell activation. Recent studies investigating the role of MHC class II + exosomes released by IECs also reported conflicting findings of either immune enhancing or immunosuppressive activities. Moreover, in addition to modulating inflammatory responses, recent findings suggest that MHC class II expression by intestinal stem cells may elicit crosstalk that promotes epithelial renewal. A more complete understanding of the different consequences of IEC MHC class II antigen presentation will guide future efforts to modulate this pathway to selectively invoke protective immunity while maintaining tolerance to beneficial antigens.


  • Open Access

    Understanding immune–microbiota interactions in the intestine

    by Philip P. Ahern, Kevin J. Maloy

    Summary: The past two decades have seen an explosion in research that aims to understand how the dynamic interplay with the gut microbiota impacts host health and disease, establishing a role for the gut microbiota in a plethora of pathologies. Understanding how health‐promoting microbiota are established and how beneficial host–microbiota interactions are maintained is of immense biomedical importance. Despite the enormous progress that has been made, our knowledge of the specific microbiota members that mediate these effects and the mechanisms underlying these interactions is rudimentary. The dearth of information regarding the nature of advantageous host–microbiota interactions, and the factors that cause these relationships to go awry, has hampered our ability to realize the therapeutic potential of the microbiota. Here we discuss key issues that limit current knowledge and describe a path forwards to improving our understanding of the contributions of the microbiota to host health.


  • Open Access

    Plasmodium vivax Infection Impairs Regulatory T-Cell Suppressive Function During Acute Malaria

    by Pedro A C Costa, Maria M Figueiredo, Suelen Q Diniz, Ana P M M Peixoto, Kevin J Maloy, Andréa Teixeira-Carvalho, Mauro S Tada, Dhelio B Pereira, Ricardo T Gazzinelli, Lis R V Antonelli

    The balance between pro- and antiinflammatory mechanisms is essential to limit immune-mediated pathology, and CD4+ forkhead box P3 (Foxp3+) regulatory T cells (Treg) play an important role in this process. The expression of inhibitory receptors regulates cytokine production by Plasmodium vivax-specific T cells. Our goal was to assess the induction of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen (CTLA-4) on Treg during malaria and to evaluate their function. We found that P. vivax infection triggered an increase in circulating Treg and their expression of CTLA-4 and PD-1. Functional analysis demonstrated that Treg from malaria patients had impaired suppressive ability and PD-1+Treg displayed lower levels of Foxp3 and Helios, but had higher frequencies of T-box transcription factor+ and interferon-gamma+ cells than PD-1−Treg. Thus malaria infection alters the function of circulating Treg by triggering increased expression of PD-1 on Treg that is associated with decreased regulatory function and increased proinflammatory characteristics.